Claritev Corporation

NYSE:CTEV 株式レポート

時価総額:US$362.1m

Claritev 将来の成長

Future 基準チェック /06

Claritevは、7.8%と3.8%でそれぞれ年率7.8%で利益と収益が成長すると予測される一方、EPSはgrowで7.8%年率。

主要情報

7.8%

収益成長率

7.85%

EPS成長率

Healthcare Services 収益成長21.7%
収益成長率3.8%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日13 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 May 05

CTEV: Volume Resilience And 2026 Buybacks Will Support Future Upside

Claritev's analyst fair value has been revised from $42.75 to $39.80 as analysts factor in slightly lower profit margin assumptions and a small reset in future P/E expectations, in line with recent price target trims from several firms following updated guidance and investment plans. Analyst Commentary Street research on Claritev has shifted toward more conservative assumptions on margin, revenue mix and investment timing, while still highlighting areas where execution could support the current valuation over time.
Seeking Alpha Apr 20

Claritev: Compounding Debt Meets Legacy Business Stabilization (Rating Upgrade)

Summary Claritev is upgraded to 'Hold' after a 32% decline, with the short thesis largely played out. Legacy business revenues are stabilizing, showing 6.2% YoY Q4 growth and accelerating full-year growth, despite margin pressure from regulatory changes. BenInsights' failed pivot is now fully reflected in CTEV’s valuation; any positive developments could act as catalysts. CTEV’s $4.6B debt load and negligible free cash flow keep valuation unattractive, with a 9.2x EV/EBITDA multiple deemed expensive for its risk profile. Read the full article on Seeking Alpha
ナラティブの更新 Apr 20

CTEV: Entrenched Payer Role And 2026 Buyback Capacity Will Support Upside

Claritev's analyst price target has been reset lower, with the model's fair value estimate moving from $44.75 to $42.75 as analysts factor in reduced formal targets from Citi, Guggenheim, and Wells Fargo, along with updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Claritev has coalesced around lower price targets, but the tone is mixed, with analysts highlighting both upside drivers and areas where execution and guidance keep them cautious.
ナラティブの更新 Apr 05

CTEV: Entrenched Position And Buybacks Will Support Volume Driven Earnings Power

Analysts cut the Claritev price target to $21, with updated models reflecting slightly different revenue growth, profit margin, and future P/E assumptions following recent guidance and sector research. Analyst Commentary Recent Street research on Claritev points to a reset in expectations, with several bearish analysts cutting price targets and highlighting execution and balance sheet risks, even as ratings in the sample remain unchanged.
ナラティブの更新 Mar 22

CTEV: Entrenched Position And Buybacks Will Support More Sustainable Future Margins

Analysts have reduced the Claritev price target to $21 from $33, reflecting updated expectations for slower revenue growth, slightly lower profit margins, and a lower future P/E multiple, even as they cite solid recent results and continued investment in growth initiatives. Analyst Commentary Recent research updates show a clear reset in expectations for Claritev, with multiple firms cutting price targets while generally maintaining existing ratings.
ナラティブの更新 Mar 07

CTEV: Entrenched Payer Role And 2026 Guidance Reset Will Support Upside

The analyst price target for Claritev has been reduced from $57.25 to $44.75. Analysts cited lower revenue growth and profit margin assumptions, as well as a revised future P/E expectation following recent price target cuts from multiple firms.
ナラティブの更新 Feb 21

CTEV: Entrenched Position And Deleveraging Will Support More Sustainable Future Margins

Claritev's analyst price target has been reset lower to $63, down from $80, as analysts factor in a slightly lower future P/E assumption of 9.87x. They also note that the company remains an entrenched vendor with accelerating revenue but elevated leverage that can weigh on valuation.
ナラティブの更新 Feb 06

CTEV: Entrenched Payer Position And Deleveraging Will Support Future Upside

Analysts have trimmed their fair value estimate for Claritev to $57.25 from $85, citing updated Street price targets in the $33 to $63 range and reduced future P/E assumptions, while also acknowledging steady revenue growth and margin expectations. Analyst Commentary Bullish and cautious views on Claritev are both in play, and that split is driving a wide range of price targets and valuation opinions.
ナラティブの更新 Jan 23

CTEV: Revenue Recovery And Deleveraging Will Support More Sustainable Future Margins

Narrative Update Opening Analysts have trimmed their fair value estimate for Claritev from $80 to $33, citing a lower Street price target that ranges from $63 at the high end to $33, and a view that stronger revenue growth and steady margins are now balanced by a less premium future P/E and concerns about elevated leverage. Analyst Commentary Recent research updates on Claritev highlight a split view, with some firms still constructive on the long term while taking down price targets and others starting coverage at more neutral levels.
分析記事 Jan 18

Claritev Corporation (NYSE:CTEV) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Unfortunately for some shareholders, the Claritev Corporation ( NYSE:CTEV ) share price has dived 26% in the last...
ナラティブの更新 Jan 09

CTEV: Best In Class Margins And Deleveraging Efforts Will Support Upside

Analysts have raised their average price target on Claritev to US$74 from US$55, citing confidence in the company's ability to accelerate growth while maintaining strong margins, even as some remain cautious about leverage and valuation. Analyst Commentary Recent research paints a mixed picture around Claritev, with bullish analysts highlighting growth potential and margin strength, while more cautious voices focus on balance sheet risk and how much optimism is already reflected in the share price.
ナラティブの更新 Dec 25

CTEV: Mid Single Digit Revenue Recovery Will Support Best In Class Margins

Analysts have raised their price target on Claritev from 55 dollars to 80 dollars, citing increased confidence that the company can reaccelerate to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Recent research notes highlight a more constructive stance on Claritev's long term prospects, with the latest upgrade reflecting greater confidence in management's roadmap to restore sustainable growth while preserving strong profitability.
ナラティブの更新 Dec 11

CTEV: Best-In-Class Margins Will Support Return To Mid-Single-Digit Expansion

Claritev's analyst price target has been raised to $74 from $55, as analysts cite growing confidence that the company can return to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Bullish Takeaways Bullish analysts view the higher $74 target as reflecting renewed confidence in Claritev's ability to reaccelerate revenue growth while preserving margin discipline.
ナラティブの更新 Nov 27

CTEV: Upgraded Buy Rating Will Drive Growth Momentum and Margin Strength

Analysts have raised Claritev’s price target from $80 to $85, reflecting renewed confidence in the company’s accelerating growth and its ability to maintain strong margins. Analyst Commentary Analyst sentiment around Claritev continues to evolve as the company demonstrates a strong execution track record and new growth initiatives.
ナラティブの更新 Nov 06

CTEV: Upgraded Buy Rating Will Drive Renewed Momentum Through 2026

Narrative Update on Claritev Analysts have raised Claritev's price target from $55 to $74, citing increased confidence in the company's plan to accelerate growth and maintain industry-leading margins. Analyst Commentary Following the recent upgrade and price target revision, analysts have shared a range of insights on Claritev’s prospects and execution trajectory.
分析記事 Nov 01

Improved Revenues Required Before Claritev Corporation (NYSE:CTEV) Stock's 35% Jump Looks Justified

Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 35% gain in the last month alone...
ナラティブの更新 Oct 23

Analysts Boost Claritev Valuation Amid Growth Optimism and Strategic Developments

Analysts have raised Claritev's fair value estimate from $70.50 to $80.00. They cite growing confidence in the company's accelerated revenue growth outlook and sustained margins following the recent price target upgrade.
分析記事 Sep 09

Claritev Corporation's (NYSE:CTEV) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Despite an already strong run, Claritev Corporation ( NYSE:CTEV ) shares have been powering on, with a gain of 27% in...
ナラティブの更新 Aug 08

Digital Transformation And AI Adoption Will Drive Global Healthcare Expansion

Claritev’s future P/E has increased markedly while net profit margin has declined, indicating higher valuation despite weaker profitability, yet the consensus price target remains unchanged at $49.50. What's in the News Claritev updated full-year 2025 revenue guidance to flat to +2% versus 2024.
分析記事 Jul 30

Claritev (NYSE:CTEV) Use Of Debt Could Be Considered Risky

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 Jul 09

Claritev Corporation's (NYSE:CTEV) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 25% gain in the last month alone...
User avatar
新しいナラティブ May 30

AI And Global Partnerships Will Reshape Personalized Medicine

AI-powered analytics, digital transformation, and global expansions position Claritev to monetize higher-value healthcare solutions and tap into growing, aging populations.
分析記事 May 15

Claritev Corporation (NYSE:CTEV) Shares Fly 30% But Investors Aren't Buying For Growth

Claritev Corporation ( NYSE:CTEV ) shareholders would be excited to see that the share price has had a great month...
分析記事 Mar 20

Little Excitement Around Claritev Corporation's (NYSE:CTEV) Revenues As Shares Take 28% Pounding

Claritev Corporation ( NYSE:CTEV ) shares have retraced a considerable 28% in the last month, reversing a fair amount...
分析記事 Feb 03

There's No Escaping MultiPlan Corporation's (NYSE:MPLN) Muted Revenues Despite A 29% Share Price Rise

MultiPlan Corporation ( NYSE:MPLN ) shares have continued their recent momentum with a 29% gain in the last month...
分析記事 Dec 20

MultiPlan Corporation (NYSE:MPLN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Those holding MultiPlan Corporation ( NYSE:MPLN ) shares would be relieved that the share price has rebounded 28% in...
分析記事 Dec 13

Here's Why MultiPlan (NYSE:MPLN) Is Weighed Down By Its Debt Load

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 Oct 20

MultiPlan Corporation (NYSE:MPLN) Shares Fly 55% But Investors Aren't Buying For Growth

MultiPlan Corporation ( NYSE:MPLN ) shareholders are no doubt pleased to see that the share price has bounced 55% in...
分析記事 Aug 18

MultiPlan Corporation (NYSE:MPLN) Not Doing Enough For Some Investors As Its Shares Slump 40%

To the annoyance of some shareholders, MultiPlan Corporation ( NYSE:MPLN ) shares are down a considerable 40% in the...
分析記事 Jul 04

Little Excitement Around MultiPlan Corporation's (NYSE:MPLN) Revenues As Shares Take 46% Pounding

Unfortunately for some shareholders, the MultiPlan Corporation ( NYSE:MPLN ) share price has dived 46% in the last...
分析記事 Jul 02

MultiPlan (NYSE:MPLN) Use Of Debt Could Be Considered Risky

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 May 09

MultiPlan Corporation (NYSE:MPLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Unfortunately for some shareholders, the MultiPlan Corporation ( NYSE:MPLN ) share price has dived 29% in the last...

業績と収益の成長予測

NYSE:CTEV - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20281,085-240712373
12/31/20271,036-236N/A2094
12/31/2026993-27381813
3/31/2026979-287-36102N/A
12/31/2025965-284-12117N/A
9/30/2025951-342-11318N/A
6/30/2025936-663-5571N/A
3/31/2025927-1,177-9928N/A
12/31/2024931-1,646-11108N/A
9/30/2024943-1,53950169N/A
6/30/2024955-1,17258168N/A
3/31/2024959-63241157N/A
12/31/2023962-9263172N/A
9/30/2023958-71069172N/A
6/30/2023966-667107209N/A
3/31/20231,018-617153242N/A
12/31/20221,080-573283372N/A
9/30/20221,137102286378N/A
6/30/20221,175161345436N/A
3/31/20221,161100338429N/A
12/31/20211,118102320405N/A
9/30/20211,075-96338416N/A
6/30/20211,010-463317390N/A
3/31/2021941-472329401N/A
12/31/2020938-521307377N/A
9/30/2020929-335281349N/A
6/30/2020951-42268335N/A
3/31/202099011294361N/A
12/31/201998310N/A284N/A
12/31/20181,04136N/A292N/A
12/31/20171,067648N/A369N/A

アナリストによる今後の成長予測

収入対貯蓄率: CTEV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CTEV今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CTEV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CTEVの収益 ( 3.8% ) US市場 ( 11.7% ) よりも低い成長が予測されています。

高い収益成長: CTEVの収益 ( 3.8% ) 20%よりも低い成長が予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: CTEVの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/05/21 11:44
終値2026/05/21 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Claritev Corporation 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8

アナリスト機関
Steven ValiquetteBarclays
Glen SantangeloBarclays
Andrew D'SilvaB. Riley Securities, Inc.